You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
SBC: BIOFLUIDICA, INC. Topic: 102Abstract Acute lymphoblastic leukemiaALLis the most common malignant disease in childhood and accounts for approximatelyof all cancers diagnosed before the age ofyearsThe primary cause of death for ALL patients is disease relapseThereforemonitoring for minimal residual diseaseMRDis considered the most powerful predictor of outcome in acute leukemiasincluding B type acute lymphoblastic leukemiaB AL ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Continuous Monitoring of COVID-19 Symptomatology for Elderly Patients in Long Term Care Facilities Using Advanced, Soft, and Flexible Sensors Mounted on the Suprasternal Notch
SBC: Sonica LLC Topic: NIAPROJECT SUMMARY: COVID-19 is significantly more lethal in the elderly1 with the greatest risk in those cared for in long-term care facilities (LTCs) where mortality rates range from 19% to 72% worldwide. Monitoring COVID-19 infections in LTCs remains a particular challenging. The existing and a continued expected shortage of sufficient molecular COVID-19 testing coupled to false negative rates as ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Microparticle Therapy for Cerebral Amyloid Angiopathy
SBC: KARAMEDICA, INC. Topic: NIAABSTRACTCerebral Amyloid AngiopathyCAAa microvasculopathy in which beta amyloidAaccumulates in the walls of cerebral blood vesselsis associated with vascular fragility and bleeding secondary to blood vessel wall breakdownCAA is especially deleterious to vascular smooth muscle cellsVSMCCAA is found inof AD casesincreases hemorrhagic stroke riskand is exacerbated by amyloid immunotherapy thereby com ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
BT-11: A First-in-class Oral Therapeutic for Inflammatory Bowel Disease
SBC: Biotherapeutics, Inc. Topic: NIAIDBTA First in class Oral Therapeutic for Inflammatory Bowel Disease Biotherapeutics IncBTIdevelops oral first in class therapeutics for autoimmune diseasesBTa lead compound for treating inflammatory bowel diseaseIBDbelongs to a new chemotype and targets the novel Lanthionine Synthetase C LikeLANCLpathwayBTI will file an IND for BTinmonthsSignificanceIBD afflicts overmillion Americans andmillion peo ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a biologic for non-hormonal contraception
SBC: MUCOMMUNE, LLC Topic: NICHDThere is a critical need for improved contraceptive methods both in the U Sand worldwideNearly half of all pregnancies in the U Sare unintendedand globally there are overmillion unintended pregnancies each yearUnintended pregnancies represent a $Bcost burden to the health system across the federal and state levels in the U SaloneThe majority of unintended pregnancies are concentrated in women who ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Advanced Nucleation Technologies for Membrane Protein Crystallization to Accelerate Structure-Based Drug Design for Substance Use Disorders
SBC: DENOVX, LLC Topic: NIDAPROJECT SUMMARY The goal of this Phase I proposal is to improve membrane protein crystallization outcomes using bifunctionalhydrophilic hydrophobicself assembled monolayersSAMsas a substrate that interacts with the bicelle envelope and indirectly preconcentrates and preorganizes membrane proteins to facilitate nucleation and crystal growthOf thehuman membrane proteins potentially relevant to drug ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections
SBC: Arrevus, Inc. Topic: NIAIDUrinary tract infectionsUTIsare one of the most common hospital acquired infections and are often caused by multi drug resistantMDRbacterial pathogensMDR bacterial pathogens are associated with significant morbidity and mortalitycreating enormous healthcare and economic burdens due to variations in disease natural histories as well as the lack of effective therapeutic optionsTreatment option limit ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Innovative TME-specific Pro-CAR T-cells for Immunotherapy of Solid Tumors
SBC: Panacise Bio, Inc. Topic: 102Abstract This project seeks to develop the next generation pro CARs that are inactive in normal tissues but selectively activated in the tumor microenvironmentTMEThe project is based on our previous development of a novel class of chimeric antigen receptors on the basis of single domain antibody mimics that recognize ErbB family membersSDAErbBon the surface of cancer cellsWe propose two specific a ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Topical selective T-type blockers for the treatment of neuropathic pain
SBC: DERMAXON LLC Topic: 105Project SummaryAbstract Paclitaxel is widely used throughout the field of oncology with indications for the treatment of a number of solid tumorsThe most commonly reported neurotoxic effect of paclitaxel is peripheral sensory neuropathy which often limits the dose and frequency of paclitaxel treatmentNeuropathic pain management is currently aimed only at reducing symptoms and treatment of chronic ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Optimization of Novel Ryanodine Receptor Modulatory Compounds for Alzheimer's Disease
SBC: NeuroLucent Topic: NIAAbstract Summary Currentlythere are no effective treatments to preserve cognitive function in AD patients and the recent series of disappointing clinical trials highlight the need to explore alternative pathwaysTo this endNeuroLucent Incand its academic partnerRFUMSare developing small molecule compounds designed as allosteric modulators of the ryanodine receptorRyRa high conductance calcium chann ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health